The primary endpoint will be the seroprotection rate which is defined as the proportion of subjects with HAI titer ≥ 40. 3 weeks post vaccination [clinicaltrials_resource:543b0d08b98e1941c597d3d0cee6d3ca]
Serum samples will be tested for anti-hemagglutinin (HA) antibodies by hemagglutination inhibition (HAI).
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
The primary endpoint will be the seroprotection rate which is defined as the proportion of subjects with HAI titer ≥ 40. 3 weeks post vaccination [clinicaltrials_resource:543b0d08b98e1941c597d3d0cee6d3ca]
Serum samples will be tested for anti-hemagglutinin (HA) antibodies by hemagglutination inhibition (HAI).
Bio2RDF identifier
543b0d08b98e1941c597d3d0cee6d3ca
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:543b0d08b98e1941c597d3d0cee6d3ca
measure [clinicaltrials_vocabulary:measure]
The primary endpoint will be t ...... subjects with HAI titer ≥ 40.
time frame [clinicaltrials_vocabulary:time-frame]
3 weeks post vaccination
description
Serum samples will be tested f ...... gglutination inhibition (HAI).
identifier
clinicaltrials_resource:543b0d08b98e1941c597d3d0cee6d3ca
title
The primary endpoint will be t ...... ≥ 40. 3 weeks post vaccination
@en
type
label
The primary endpoint will be t ...... b0d08b98e1941c597d3d0cee6d3ca]
@en